
Olivier has served as CEO of IBA since 2012. He graduated from the Vrije Universiteit Brussel in 1992 and built his career in the medical device and proton therapy sector. Before becoming CEO, he was Chief Strategy Officer at IBA Molecular Holding from 2003 to 2010, and prior to that served as CEO of Scanditronix Medical (2001 to 2003).
Under his leadership, IBA has strengthened its position as the global reference point for proton therapy systems and dosimetry solutions. The company serves cancer treatment centers worldwide and has expanded into carbon therapy and other advanced radiation modalities. IBA founder Yves Jongen remains connected to the company he created in 1986.
Across Olivier Legrain's public statements, one idea keeps resurfacing: that IBA's work is not really about technology, it is about care. He repeatedly frames the company's projects, from proton therapy centers to the Oncia Community's patient houses, as expressions of a deeper mission "to accelerate the development of ce type de maison" that helps patients keep "la joie de vivre dans la peur de mourir" . Over time this preoccupation has moved from being an implicit backdrop to product launches toward an explicit philosophy of the firm, one where he argues a company's purpose extends "far beyond short-term profit maximization" and must account for responsibility toward employees, society and the environment 15. The shift is also organizational: as IBA marks 40 years and grows to a global scale, Legrain describes reshaping his own role and the leadership team so he can "focus deeply on the strategic steering of the Group" while trusting others with operations .
Legrain consistently describes IBA's innovations, and especially its Oncia Community initiative, as evidence that "technology alone isn't enough" . He calls the effort "one of the most important innovation in cancer care. Humanizing cancer care" , and ties it to a moral obligation: "Nous avons l'obligation morale d'accélérer le développement de ce type de maison" . He credits the people driving this vision directly, praising "Gauthier Saelens pour sa vision et sa determination" and expressing eagerness to advance the cause alongside "mon cher ami Renaud" for "une cause qui nous tient tous les deux très a coeur" .
In his L'Echo podcast appearance, Legrain lays out his clearest statement of corporate philosophy: a company "is much more than profit maximization" and must weigh medium and long-term thinking rather than fixate on stock price, which he argues lets companies "manage risks better, attract talent, and create value for stakeholders while still generating profit" 15. This framing runs underneath his written posts as well, where pride is repeatedly tied not to financial results but to people and mission, as when he says the company's 40th anniversary "reminded me that our mission is only possible because of the people behind" it .
Legrain treats professional gatherings and partnerships as engines of progress, not just networking. At Amstro he emphasized that a small, high-quality conference "create[s] community among practitioners, enabling faster learning, knowledge sharing, and quicker adoption of best practices in radiation oncology" 16. He extends the same logic to IBA's customer and institutional relationships, describing a proton therapy event as gathering "a vibrant community" of "luminaries delivering the promise of Proton Therapy to thousands of patients around the world" , and thanking long-term partners like Kazakhstan's Institute of Nuclear Physics for "continued trust" built over "a decade of successful collaboration" .
In interviews, Legrain covers ground his written posts do not: the origin story of IBA itself, tracing its founding to when its creator "left UCL's cyclotron laboratory to start IBA across the street," and situating the company's growth to "2,300 employees and 500 million euros in annual revenue" over a 40-year arc 14. He also articulates, more fully than in any post, his argument against short-term profit maximization as a governing logic for companies, explicitly linking medium and long-term thinking to risk management and talent attraction 15. And at Amstro he speaks to the mechanics of professional learning, that small-scale conferences enable "quality interactions with interesting people and sessions" and speed the adoption of best practices in a way large events do not 16.
From public career histories · 13 entries
# Summary Olivier Legrain discusses IBA's 40-year journey from a university laboratory spinoff to a global company with 2,300 employees and 500 million euros in annual revenue, tracing its founding when the company's creator left UCL's cyclotron laboratory to start IBA across the street.
Olivier Legrain discusses how a company's purpose extends far beyond short-term profit maximization and must account for responsibility toward employees, society, and the environment. He argues that introducing medium and long-term thinking, rather than focusing solely on stock price, allows companies to manage risks better, attract talent, and create value for stakeholders while still generating profit.
Olivier Legrain, CEO of IBA, discusses his experience at the inaugural Amstro conference, noting that the small meeting size allowed for quality interactions with interesting people and sessions. He highlights the industry discussion about regional development commitment and a session on MRI use for liver treatment as particularly valuable. Legrain emphasizes that such conferences create community among practitioners, enabling faster learning, knowledge sharing, and quicker adoption of best practices in radiation oncology.